Illicit use of pharmaceutical opioids among young polydrug users in Ohio

Abstract This study, conducted in Columbus, Ohio, identified the predictors of current (past 30 day) illicit use of pharmaceutical opioids among young individuals ( n = 402) with a history of MDMA/ecstasy use who were recruited in 2002–2003 using respondent-driven sampling. To be eligible, participa...

Full description

Saved in:
Bibliographic Details
Published in:Addictive Behaviors 2009-08, Vol.34 (8), p.649-653
Main Authors: Daniulaityte, R, Falck, R.S, Wang, J, Carlson, R.G
Format: Article
Language:English
Subjects:
Adolescent
Adult
Amphetamine-Related Disorders - epidemiology
Analgesics, Opioid
Depression
Depression - epidemiology
Depression - psychology
Diagnosis, Dual (Psychiatry) - statistics & numerical data
Drug abuse
Drug use
Female
Hallucinogens
Humans
Male
MDMA/ecstasy
N-Methyl-3,4-methylenedioxyamphetamine
Narcotics
Ohio - epidemiology
Opioid-Related Disorders - epidemiology
Pharmaceutical drugs
Pharmaceutical opioids
Psychiatry
Regression analysis
Substance abuse
Substance-Related Disorders - epidemiology
Young Adult
Young adults
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract This study, conducted in Columbus, Ohio, identified the predictors of current (past 30 day) illicit use of pharmaceutical opioids among young individuals ( n = 402) with a history of MDMA/ecstasy use who were recruited in 2002–2003 using respondent-driven sampling. To be eligible, participants had to be 18–30 years old, not involved in a drug abuse treatment, and report MDMA/ecstasy use at least once in the past 6 months. About 81% reported lifetime, and more than 31% reported current illicit use of pharmaceutical opioids. Logistic regression analysis revealed that illicit use of pharmaceutical tranquilizers and pharmaceutical stimulants were the strongest predictors of illicit use of pharmaceutical opioids. Risk of pharmaceutical opioid use was also greater among those who had higher levels of depressive symptoms and reported current use of hallucinogens and inhalants. Our findings suggest that the non-medical use of pharmaceutical opioids is a part of polydrug use practices that often incorporate illicit use of other prescription drugs. The observed relationship between depressive symptoms and illicit use of pharmaceutical opioids may have important implications for prevention programming and should be examined in future research.
ISSN:0306-4603
1873-6327
1573-3602
DOI:10.1016/j.addbeh.2009.03.037